▪Reduced thrombin activity▪Reduced levels of transforming growth factor β1 in BAL fluid▪Reduced number of inflammatory cells and protein concentrations in BAL fluid▪Histologically evident lung inflammation and fibrosis were significantly decreased▪Reduced expression of collagen, connective tissue growth factor, and α-smooth muscle actin▪Marked anti-inflammatory and antifibrotic effects observed in a bleomycin model of pulmonary fibrosis. The gene discussed is CCN2; the disease is pulmonary fibrosis.